Why is AbbVie (ABBV) stock down today?
AbbVie stock is slipping today as drug-pricing policy uncertainty weighs on big pharma even as analyst price targets rise.
What happened
AbbVie shares fell 1.17% to $245.11 on July 14, 2026 — touching a session low of $243.19 — as concerns over the Trump administration's drug-pricing deals continued to pressure large pharmaceutical names. A Motley Fool report published today highlighted how those policy moves are reshaping revenue expectations for AbbVie alongside peers Pfizer and Bristol Myers Squibb, creating a cautious backdrop for the stock even as business fundamentals remain solid.
The decline stands out because analyst sentiment is moving in the opposite direction. BMO Capital raised its price target on AbbVie from $258 to $300 on July 13, maintaining an Outperform rating. UBS also lifted its target, from $230 to $260, though it held a Neutral rating. A Zacks analysis published this morning also noted Wall Street's optimism on the name. When a stock falls despite upward analyst revisions, the market is typically weighing a macro or policy overhang more heavily than company-specific positives.
The broader market is not pulling AbbVie lower — the S&P 500 gained 0.47% and the Nasdaq-100 (QQQ) rose 1.39% today, meaning AbbVie's decline is specific to pharma sector pressures rather than a general risk-off move. CPI data released this morning showed headline inflation cooling to a 3.8% annual rate (prior: 4.2%), and Fed Chairman Warsh testified before Congress, both of which appeared to support equities broadly — but pharma names face their own headwinds from pricing policy.
On the company side, AbbVie's SkinMedica aesthetics brand announced a continued investment in regenerative science R&D, and a separate report tied AbbVie to a nascent $2 billion aesthetics opportunity linked to GLP-1 drug trends. These are incremental pipeline developments. The company's next earnings report is scheduled for July 31, 2026, when investors will get a clearer picture of how drug-pricing negotiations are affecting actual revenue. Last quarter, AbbVie posted EPS of $2.65 against a $2.67 estimate, on revenue of $15.00 billion.
The catalysts, cited
Trump drug-pricing deals raising revenue uncertainty for AbbVie, Pfizer, and Bristol Myers Squibb
Motley Fool
BMO Capital raises AbbVie price target to $300 from $258, maintains Outperform
MT Newswires
UBS raises AbbVie price target to $260 from $230, maintains Neutral
MT Newswires
Zacks examines whether AbbVie is a buy as Wall Street analysts look optimistic
Zacks
SkinMedica deepens commitment to regenerative science R&D
PR Newswire
What to watch next
- Q2 2026 earnings report
- Core PPI m/m release
Why is PFE moving?
Why is BMY moving?
Why is JNJ moving?
Why is LLY moving?People also ask
Why is AbbVie stock going down today?
AbbVie is down about 1.17% today, primarily due to ongoing investor concern about the Trump administration's drug-pricing policy deals, which a Motley Fool report flagged as reshaping revenue expectations across big pharma. This is happening even as the broader market trades higher, signaling the pressure is pharma-specific rather than market-wide.
Why is AbbVie stock falling if analysts are raising their price targets?
BMO Capital raised its price target to $300 and UBS lifted its target to $260 on July 13, both signals of analyst optimism. However, the stock is still declining because drug-pricing policy uncertainty is acting as a near-term overhang that the market appears to be weighing more heavily than analyst revisions right now.
Is it just AbbVie or is the whole market down today?
It is largely specific to AbbVie and the pharma sector. The S&P 500 is up 0.47% and the Nasdaq-100 is up 1.39% today, so the broader market is rallying while AbbVie trades lower.
When does AbbVie report earnings next?
AbbVie's next earnings report is scheduled for July 31, 2026. Last quarter, the company reported EPS of $2.65 (just below the $2.67 estimate) on revenue of $15.00 billion, with revenue growing 12.4% year over year.